EUROLAB
usp-1191-stability-considerations-in-compounding-pharmacy-products
Stability Studies (ICH Guidelines) BP Appendix XVI Stability of Finished Products with PreservativesBP Stability Evaluation of Modified Release PreparationsEMA CHMP/QWP/609/2014 Quality Requirements for Stability of BiosimilarsEMA CPMP/QWP/122/02 Stability Testing for Transdermal PatchesEMA Guideline for Stability of Veterinary Medicinal ProductsEMA Guideline on Holding Times for Bulk Products (Stability Implication)EMA Guideline on Stability Testing for Liposomal Drug FormulationsEMA Guideline on Stability Testing for Orally Inhaled ProductsEMA Reflection Paper on Stability for Polymers in Drug DeliveryEMA Reflection Paper on Stability of Advanced Therapies (ATMPs)EMA Stability Testing for Nanoparticle FormulationsEMA Stability Testing in Pediatric FormulationsEMA Stability Testing of Drug-Device Combination ProductsEP 1.2.1 Drug Substance Stability in Multisource SubmissionsEP 2.9.5 Uniformity of Mass Post-Stability TestingEP 3.2.1 Container Closure System Stability EvaluationEP 5.20 Climatic Conditions in Stability Storage ChambersEP 6.0 Stability Testing Requirements for MonographsEP 6.1 Real-Time Stability Testing of Biological ExtractsEP Climatic Zones IVa and IVb for ASEAN and African MarketsFDA 21 CFR 211.166 Stability Program Requirements for PharmaceuticalsFDA 21 CFR 610.17 Stability Testing of Biological ProductsFDA Accelerated Stability Protocol for Veterinary DrugsFDA cGMP Guidelines for Expiration Dating and Stability StudiesFDA Container Closure Stability Evaluation for Ophthalmic ProductsFDA Draft Guidance for Stability of Inhaled Cannabis ProductsFDA Draft Guidance on Cannabis Stability Testing in Drug DevelopmentFDA Guidance for Allergenic Products Stability AssessmentFDA Guidance for Industry: Stability Testing for Nutritional SupplementsFDA Guidance on Freeze-Thaw Stability Testing for BiologicsFDA Post-Approval Changes and Stability RequirementsFDA Q&A Guidance for Stability of Topical Dermatologic ProductsFDA Requirements for Drug Substance Holding Time & StabilityFDA Requirements for Orphan Drugs and Niche Stability StudiesICH E2E Pharmacovigilance & Stability Shelf-life ManagementICH E3 Stability Documentation in Clinical Study ReportsICH E6(R2) GCP Considerations in Clinical Trial Stability SamplesICH M10 Bioanalytical Method Validation in Stability TestingICH M4Q Stability Data Compilation for Common Technical Document (CTD)ICH M9 Stability of Biowaiver-Based Generic SubmissionsICH Q10 Pharmaceutical Quality System and Stability OversightICH Q11 Stability of Drug Substances in Developmental StagesICH Q12 Lifecycle Management and Ongoing Stability MonitoringICH Q14 Analytical Procedure Development in Stability StudiesICH Q1A(R2) Accelerated Stability Testing of Solid Oral Dosage FormsICH Q1B Photostability Testing for Light-Sensitive Drug ProductsICH Q1C Stability Testing for New Dosage Forms (Capsules, Tablets, etc.)ICH Q1D Bracketing and Matrixing Design Stability Protocol DevelopmentICH Q1E Evaluation of Stability Data for Regulatory SubmissionsICH Q1F Stability Data Requirements for Global RegistrationICH Q2(R1) Validation of Analytical Procedures in Stability StudiesICH Q3B(R2) Stability Testing of Impurities in Drug ProductsICH Q3C Residual Solvent Stability in Finished Dosage FormsICH Q4 Guidelines for Pharmacopoeial Stability HarmonizationICH Q4B Annex Stability-Related Harmonization for Global FilingICH Q5C Stability Testing of Biotechnological/Biological ProductsICH Q5D Derivation and Stability of Cell SubstratesICH Q6B Specifications Testing for Biotech Products in Long-Term StudiesICH Q8 Design Space for Stability-Critical ParametersICH Q9 Risk-Based Stability Planning and Protocol DesignICH S3B Photostability of Biologics in Animal StudiesICH S4 Stability of New Veterinary Drug Substances and ProductsICH S6(R1) Preclinical Stability of Biotech ProductsISO 10993-1 Biocompatibility Stability Studies in Medical DevicesISO 11607 Package Integrity Stability for Sterile Medical DevicesISO 13408 Stability Testing of Aseptic Processing SystemsISO 14644 Environmental Monitoring for Stability ChambersISO 14971 Risk Management Related to Stability FailuresISO 15378 GMP for Primary Packaging Stability InteractionsISO 17025 Stability Testing Accreditation RequirementsISO 17034 Reference Material Stability and HomogeneityISO 20387 Stability Assessment in Biobanking Sample StorageISO 21973 Transport Stability of Cell-Based TherapiesISO 9001:2015 Quality System Requirements for Stability ProgramsUSP <1046> Cellular and Gene Therapy Product StabilityUSP <1049> Excipient Stability and Shelf-Life EvaluationUSP <1079> Storage and Stability Testing in Distribution SystemsUSP <1086> Impurities Testing within Stability ProtocolsUSP <1090> Assessment of Drug Product Performance Post StabilityUSP <1118> Monitoring Stability in Storage and Transport ConditionsUSP <1168> Stability Testing for RadiopharmaceuticalsUSP <1224> Transfer of Analytical Procedures in Stability StudiesUSP <1225> Validation of Compendial Procedures in Stability ContextUSP <1226> Verification of Compendial Procedures Post-StabilityUSP <671> Stability Testing of Packaging MaterialsUSP <795> Stability Evaluation of Nonsterile PreparationsUSP <797> Stability Testing of Sterile Preparations in CleanroomsWHO Annex 10 Stability Testing of Active Pharmaceutical IngredientsWHO Annex 7 Stability of Reconstituted Lyophilized ProductsWHO Annex 9 Stability for Zoonotic Biological ProductsWHO Good Storage and Distribution Practices for StabilityWHO Guidelines for Stability of DNA and mRNA VaccinesWHO Guidelines on Stability of Combination ARV TherapiesWHO Stability of Monoclonal Antibodies Under Accelerated ConditionsWHO Stability Requirements for Medical Oxygen and InhalersWHO Stability Testing for Pre-Filled Syringes and Auto-InjectorsWHO Temperature Mapping and Qualification of Stability ChambersWHO TRS 1003 Stability Protocols for Combination ProductsWHO TRS 1010 Stability Testing for Vaccines under Cold Chain ConditionsWHO TRS 1019 Stability Testing of Blood and Blood ProductsWHO TRS 953 Climatic Zone-Based Stability Testing for Global MarketsWHO TRS 970 Real-Time Stability Assessment for WHO PrequalificationWHO TRS 992 Long-Term Stability Testing for Herbal Medicinal Products

USP <1191> Stability Considerations in Compounding Pharmacy Products: Laboratory Testing Services

The United States Pharmacopeia (USP) is a non-profit organization that develops and publishes standards for pharmaceuticals, including compounding pharmacy products. USP <1191> Stability Considerations in Compounding Pharmacy Products is one such standard that outlines the requirements for testing the stability of compounded preparations.

Relevant Standards

The following international and national standards govern the testing service:

  • ISO 17025:2017 (General Requirements for the Competence of Testing and Calibration Laboratories)
  • ASTM E2539-09 (Standard Practice for Stability Studies in Compounded Preparations)
  • EN 14643-1:2009 (Chemical disinfectants and antiseptics - Quantitative suspension test for the evaluation of bactericidal activity - Test method and requirements)
  • TSE (Turkish Standards Institution) KEN 1168:2015 (Sterility testing of pharmaceutical products)
  • Standard Development Organizations

    The development and maintenance of standards are overseen by standard development organizations, such as:

  • USP
  • International Organization for Standardization (ISO)
  • American Society for Testing and Materials (ASTM)
  • European Committee for Standardization (CEN)
  • These organizations collaborate to ensure that standards are aligned and up-to-date.

    Standard Evolution and Updates

    Standards evolve over time to reflect changes in technology, science, and regulatory requirements. Updates are made through a rigorous process involving:

    1. Research and development

    2. Public comment periods

    3. Review and approval by standard development organizations

    Standard Numbers and Scope

    Some relevant standard numbers and their scope include:

  • USP <1191> (Stability Considerations in Compounding Pharmacy Products)
  • ISO 17025:2017 (General Requirements for the Competence of Testing and Calibration Laboratories)
  • ASTM E2539-09 (Standard Practice for Stability Studies in Compounded Preparations)
  • Industry-Specific Examples

    Compounded preparations are used extensively in various industries, including:

    1. Pharmaceutical

    2. Cosmetic

    3. Food

    Each industry has its unique requirements and regulations.

    Standard Compliance Requirements

    Compliance with standards is mandatory for laboratories providing testing services, particularly in the pharmaceutical and compounding industries.

    Business and Technical Reasons for Testing

    The business and technical reasons for conducting USP <1191> Stability Considerations in Compounding Pharmacy Products testing include:

  • Ensuring product safety and efficacy
  • Compliance with regulations and standards
  • Maintaining quality assurance and control
  • Building customer trust and confidence
  • Consequences of Not Performing the Test

    Failure to conduct this test can result in:

  • Non-compliance with regulations
  • Product recalls or bans
  • Loss of business reputation and revenue
  • Safety risks for consumers
  • Risk Factors and Safety Implications

    Compounded preparations pose unique risks due to their customized nature, which requires careful consideration during testing.

    Quality Assurance and Quality Control Aspects

    Testing services must adhere to quality assurance and control principles, including:

  • Calibration and validation of equipment
  • Training and competence of personnel
  • Record-keeping and documentation
  • Competitive Advantages and Cost-Benefit Analysis

    Performing this test provides competitive advantages, including:

  • Improved product safety and efficacy
  • Enhanced customer trust and confidence
  • Compliance with regulations and standards
  • Reduced risk of product recalls or bans
  • The cost-benefit analysis demonstrates that investing in testing services can lead to long-term benefits and savings.

    Testing Equipment and Instruments

    The following equipment and instruments are used for USP <1191> Stability Considerations in Compounding Pharmacy Products testing:

  • Incubators
  • Refrigerators
  • Centrifuges
  • Analytical balance
  • Spectrophotometer
  • Testing Environment Requirements

    The testing environment must be controlled to ensure accuracy and precision, including:

  • Temperature (20C 5C)
  • Humidity (60 10)
  • Pressure (1 atm)
  • Sample Preparation Procedures

    Samples are prepared according to established procedures, including:

  • Weighing and mixing
  • Filtration and sterilization
  • Testing Parameters and Conditions

    The testing parameters and conditions include:

  • Time (7 days, 30 days, or 6 months)
  • Temperature (2C to 8C or 25C 5C)
  • Humidity (60 10)
  • Light exposure
  • Measurement and Analysis Methods

    Measurement and analysis methods include:

  • High-performance liquid chromatography (HPLC)
  • Gas chromatography (GC)
  • Spectrophotometry
  • Calibration and Validation Procedures

    Equipment calibration and validation procedures are conducted regularly, including:

  • Instrument calibration
  • Method validation
  • Performance verification
  • Quality Control Measures During Testing

    Quality control measures during testing include:

  • Regular monitoring of equipment performance
  • Documentation of test results
  • Training and competence of personnel
  • Test Results and Reporting

    Test results are documented and reported according to established procedures, including:

  • Data analysis and interpretation
  • Report writing and submission
  • Interpretation of Test Results

    Test results are interpreted in accordance with established guidelines and regulations.

    Conclusion

    USP <1191> Stability Considerations in Compounding Pharmacy Products testing is a critical component of ensuring product safety and efficacy. Laboratories providing testing services must adhere to standard requirements, including calibration, validation, and quality control procedures. By performing this test, laboratories can demonstrate compliance with regulations and standards, build customer trust and confidence, and reduce risk of product recalls or bans.

    Persuasive Conclusion

    In conclusion, USP <1191> Stability Considerations in Compounding Pharmacy Products testing is an essential service that requires careful consideration and adherence to standard requirements. Laboratories providing this testing service can demonstrate their commitment to quality assurance and control, ensuring the safety and efficacy of compounded preparations. By investing in this testing service, laboratories can build customer trust and confidence, reduce risk, and maintain a competitive edge in the market.

    References

  • USP <1191> (Stability Considerations in Compounding Pharmacy Products)
  • ISO 17025:2017 (General Requirements for the Competence of Testing and Calibration Laboratories)
  • ASTM E2539-09 (Standard Practice for Stability Studies in Compounded Preparations)
  • Need help or have a question?
    Contact us for prompt assistance and solutions.

    Latest News

    View all

    JOIN US
    Want to make a difference?

    Careers